Establishment of primary patient-derived xenografts of palliative TURP specimens to study castrate-resistant prostate cancer.

BACKGROUND - Fresh patient specimens of castrate-resistant prostate cancer (CRPC) are invaluable for studying tumor heterogeneity and responses to current treatments. They can be used for primary patient-derived xenografts (PDXs) or serially transplantable PDXs, but only a small proportion of samples grow successfully. To improve the efficiency and quality of PDXs, we investigated the factors that determine the initial engraftment of patient tissues derived from TURP specimens.

METHODS - Fresh tissue was collected from castrate patients who required a TURP for urinary symptoms. Tissue was grafted under the renal capsule of immune-compromised mice for up to 14 weeks. The abundance of cancer in ungrafted and grafted specimens was compared using histopathology. Mice were castrated or implanted with testosterone pellets to determine the androgen-responsiveness of CRPC PDXs from TURP tissue.

RESULTS - Primary PDXs were successfully established from 7 of 10 patients that underwent grafting. Of the 112 grafts generated from these 10 patients, 21% contained cancer at harvest. Grafts were most successful when the original patient specimens contained high amounts of viable cancer, defined as samples with (i) at least 50% cancer cells, (ii) no physical damage, and (iii) detectable Ki67 expression. PDX grafts survived in castrated hosts and proliferated in response to testosterone, confirming that they were castrate resistant but androgen-responsive.

CONCLUSIONS - Primary PDXs of CRPC can be established from TURP specimens with modest success. The take rate can be increased if the original tissues contain sufficient numbers of actively proliferating cancer cells. Selecting specimens with abundant viable cancer will maximize the rate of engraftment and increase the efficiency of establishing PDXs that can be serially transplanted. Prostate 9999: XX-XX, 2015. © 2015 Wiley Periodicals, Inc.

Prostate. 2015 Jul 14. doi: 10.1002/pros.23039. [Epub ahead of print]

Lawrence MG1, Pook DW1,2, Wang H1, Porter LH1, Frydenberg M1,3,4, Kourambas J3, Appu S3,4, Poole C3, Beardsley EK1, Ryan A5, Norden S5, Papargiris MM1, Risbridger GP1, Taylor RA6.

1 Department of Anatomy and Developmental Biology, Monash University, Clayton, Victoria, Australia.
2 Department of Oncology, Monash Cancer Centre, Melbourne, Victoria, Australia.
3 Department of Urology, Monash Medical Centre, Clayton, Victoria, Australia.
4 Department of Surgery, Monash University, Clayton, Victoria, Australia.
5 TissuPath Pathology, Melbourne, Mount Waverley, Victoria, Australia.
6 Department of Physiology, Monash University, Clayton, Victoria, Australia.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe